SCHEMBL354473

SCHEMBL354473

CN(Cc1csc(NC(=O)NCc2csc(Cl)c2)n1)C(=O)C1CCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.42
RAB9A P51151 5/20 0.40
LMNA P02545 6/20 0.40
MAPK1 P28482 3/20 0.40
HPGD P15428 2/20 0.40
NPC1 O15118 6/20 0.37
ALDH1A1 P00352 4/20 0.37
ELOVL1 Q9BW60 1/20 0.37
KDM4E B2RXH2 2/20 0.37
TSHR P16473 2/20 0.36
HSD17B10 Q99714 1/20 0.36
ROCK1 Q13464 3/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
POLB P06746 1/20 0.36
CLK1 P49759 1/20 0.36
HTT P42858 1/20 0.36
GRM5 P41594 1/20 0.35
ROCK2 O75116 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353708 0.86 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ALMNAMAPK1HPGD
SCHEMBL19119502 0.86 ROCK1 (0.35) SMN1; SMN2RAB9ALMNAMAPK1HPGD
SCHEMBL352739 0.85 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ALMNAMAPK1HPGD
SCHEMBL352738 0.85 SMN1; SMN2 (0.38) SMN1; SMN2RAB9ALMNAMAPK1HPGD
SCHEMBL353388 0.84 ROCK2 (0.50) SMN1; SMN2RAB9ALMNANPC1ALDH1A1
SCHEMBL354062 0.84 ROCK2 (0.50) SMN1; SMN2RAB9ALMNANPC1ALDH1A1
SCHEMBL353453 0.84 ROCK2 (0.50) SMN1; SMN2RAB9ALMNANPC1ALDH1A1
SCHEMBL353243 0.84 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ALMNAMAPK1HPGD
SCHEMBL353295 0.82 ROCK2 (0.49) SMN1; SMN2RAB9ALMNANPC1ROCK1
SCHEMBL353755 0.81 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ALMNAMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA SMN1; SMN2 2356/4885RAB9A 1714/4885LMNA 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.